Drug-induced intracerebral hemorrhage

Συγγραφείς: A. I. Listratov, T. M. Ostroumova, A. I. Kochetkov, O. D. Ostroumova

Πηγή: Качественная клиническая практика, Vol 0, Iss 2, Pp 55-68 (2022)

Θεματικοί όροι: лекарственно-индуцированное внутримозговое кровоизлияние, селективные ингибиторы обратного захвата серотонина, 3. Good health, RS1-441, 03 medical and health sciences, статины, Pharmacy and materia medica, 0302 clinical medicine, тромболитические препараты, Medical technology, антиагреганты, нежелательные лекарственные реакции, R855-855.5, внутримозговое кровоизлияние, антикоагулянты

Σύνδεσμος πρόσβασης: https://doaj.org/article/7b12447e21ad4802a92cd519ed199225

Оценка обоснованности назначения антиагрегантной терапии пациентам кардиологического профиля ; Assessment of the validity of prescribing antiplatelet therapy to patients with a cardiological profile

Συγγραφείς: Lykova, E. A., Grishin, V. A., Styazhkinа, J. A., Grishina, I. F., Лыкова, Е. А., Гришин, В. А., Стяжкина, Ю. А., Гришина, И. Ф.

Πηγή: Сборник статей

Θεματικοί όροι: ANTIPLATELET AGENTS, CVD PREVENTION, VALIDITY OF THERAPY, АНТИАГРЕГАНТЫ, ПРОФИЛАКТИКА ССЗ, ОБОСНОВАННОСТЬ ТЕРАПИИ

Περιγραφή αρχείου: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения : Сборник статей IX Международной научно-практической конференции молодых ученых и студентов, 17-18 апреля 2024 г. Т. 1.; http://elib.usma.ru/handle/usma/21189

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/21189

Система гемостазу та її регуляція при порушенні функціональної здатності нирок

Συγγραφείς: Melnyk, O.O.

Πηγή: Počki, Vol 6, Iss 3.17, Pp 57-75 (2016)
KIDNEYS; № 3.17 (2016); 57-75
Почки-Počki; № 3.17 (2016); 57-75
Нирки-Počki; № 3.17 (2016); 57-75

Θεματικοί όροι: anticoagulants, antithrombotic therapy in uremic patients, hemostasis system research algorithm, coagulation cascade, Diseases of the genitourinary system. Urology, 3. Good health, platelets, hemostasis, impaired renal function, antiplatelet agents, uremic bleeding and antithrombotic therapy, гемостаз, порушення функції нирок, тромбоцити, коагуляційний каскад, антикоагулянти, антиагреганти, терапія уремічних кровотеч, антитромботична терапія в уремічних пацієнтів, алгоритм дослідження системи гемостазу, нарушение функции почек, тромбоциты, коагуляционный каскад, антикоагулянты, антиагреганты, терапия уремических кровотечений, антитромботическая терапия у уремических пациентов, алгоритм исследования системы гемостаза, RC870-923

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: https://doaj.org/article/f9e913f075be4ae7a73af190855ede18
https://core.ac.uk/display/87776788
http://kidneys.zaslavsky.com.ua/article/download/76541/116315
http://kidneys.zaslavsky.com.ua/article/view/76541
http://kidneys.zaslavsky.com.ua/article/view/76541

Opportunities for preeclampsia prevention: today and tomorrow

Συγγραφείς: Guryeva, V. M., Travkina, A. A., Matveev, M. O., Morokhotova, L. S., Kotov, Y. B., Semenova, T. A.

Πηγή: Репродуктивная эндокринология, Vol 0, Iss 55, Pp 99-104 (2020)
Reproductive Endocrinology; № 55 (2020); 99-104
Репродуктивная эндокринология; № 55 (2020); 99-104
Репродуктивна ендокринологія; № 55 (2020); 99-104

Θεματικοί όροι: прееклампсія, плацента-асоційовані ускладнення, профілактика прееклампсії, антиагреганти, гепарин, preeclampsia, 03 medical and health sciences, placenta-associated complications, prevention of preeclampsia, antiplatelet agents, heparin, 0302 clinical medicine, RG1-991, преэклампсия, плацента-ассоциированные осложнения, профилактика преэклампсии, антиагреганты, Gynecology and obstetrics, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://reproduct-endo.com/article/download/218465/218122
https://doaj.org/article/3b78f19143914a419c9aaaab6d10aa29
https://doaj.org/article/3b78f19143914a419c9aaaab6d10aa29
http://reproduct-endo.com/article/download/218465/218122
http://reproduct-endo.com/article/view/218465
http://reproduct-endo.com/article/view/218465

Персонализированная стратегия двойной антиагрегантной терапии у пациентов с острым коронарным синдромом, стабильной ишемической болезнью сердца и после ишемического инсульта

Θεματικοί όροι: Grelorta, ишемический инсульт, двойная антитромбоцитарная терапия, стабильная ишемическая болезнь сердца, Грелорта, stable coron­ary artery disease, acetylsalicylic acid, острый коронарный синдром, dual antiplatelet therapy, ticagrelor, acute coronary syndrome, тикагрелор, ischemic stroke, антиагреганты, кровотечение, antiplatelet agents, bleeding, ацетилсалициловая кислота

Comparative study of the CYP2C19, CYP2C9, CYP4F2 gene polymorphisms impact on the clinical and laboratory characteristics of acute coronary syndrome patients ; Сравнительная оценка влияния носительства полиморфизма генов CYP2C19, CYP2C9, CYP4F2 на клинико-лабораторные особенности пациентов с острым коронарным синдромом

Συγγραφείς: B. I. Kantemirova, M. A. Abdullaev, E. N. Chernysheva, I. Z. Kitiashvili, Z. V. Zharkov, A. N. Romanova, E. R. Konovalova, Б. И. Кантемирова, М. А. Абдуллаев, Е. Н. Чернышева, И. З. Китиашвили, З. В. Жаркова, А. Н. Романова, Е. Р. Коновалова

Συνεισφορές: This scientific study was carried out with the support of the funds provided by the state assignment of the Ministry of Health of the Russian Federation "Development of algorithms for personalized prescription of antiplatelet agents in patients with acute coronary syndrome", for the period of 2021–2023., Научное исследование осуществлено за счёт средств государственного задания Министерства здравоохранения Российской Федерации «Разработка алгоритмов персонализированного назначения антиагрегантов у пациентов с острым коронарным синдромом», годы выполнения 2021–2023 гг.

Πηγή: Pharmacogenetics and Pharmacogenomics; № 1 (2023); 46-55 ; Фармакогенетика и фармакогеномика; № 1 (2023); 46-55 ; 2686-8849 ; 2588-0527

Θεματικοί όροι: полиморфизм, antiplatelet agents, clopidogrel, CYP2C19, CYP2C9, CYP4F2, polymorphism, антиагреганты, клопидогрел

Περιγραφή αρχείου: application/pdf

Relation: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/274/264; Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016 Jan 26;133(4):e38–60. DOI:10.1161/CIR.0000000000000350.; Giacoppo D, Matsuda Y, Fovino LN, et al. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with secondgeneration drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. European heartjournal. 2021 Jan 21;42(4):308–19. DOI:10.1093/eurheartj/ehaa739; Bhatt DL, Hulot JS, Moliterno DJ, Harrington RA. Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res. 2014;114(12):1929–1943. DOI:10.1161/circresaha.114.302737.; Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease—implications for personalized medicine. Pharmacologicalreviews. 2013 Jul 1;65(3):987–1009. DOI:10.1124/pr.112.007252.; Федина Л.В., Мирзаев К.Б., Сычёв Д.А., и др. Влияние носительства клинически значимых аллельных вариантов генов CES1, PON1, ABCG2, CYP4F2, CYP3A4, IGTB3, P2Y12, PEAR1, B4GALT2 на антиагрегантное действие клопидогрела и клинические исходы пациентов с ОКС и фибрилляцией предсердий. Фармакогенетика и фармакогеномика. 2021;(2):19–20. [Fedina LV, Mirzoev KB, SychevDA, et al. The effect of carrying clinically significant allelic variants of the CS 1,PON1, ABCG2, CYP4F2, CYP3A4, IGTB3, P2Y12, PEAR 1, B4GALT2 genes on the antiplatelet effect of clopidogrel and clinical outcomes of patients with ACS and atrial fibrillation. Farmakogenetika i farmakogenomika = Pharmacogenetics and pharmacogenomics. 2021;(2):19–20. (In Russ.)]. DOI:10.37489/2588-0527-2020-2-19-20.; Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Journal of Thrombosis and Haemostasis. 2007 Dec 1;5(12):2429–36. DOI:10.1111/j.1538-7836.2007.02775.x.; Tatarunas V, Jankauskiene L, Kupstyte N, et al. The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy. Blood Coagulation & Fibrinolysis. 2014 Jun 1;25(4):369–74. DOI:10.1097/MBC.0000000000000053.; Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. New England journal of medicine. 2009 Jan 22;360(4):354–62. DOI:10.1056/nejmoa0809171.; Fritsma GA. Platelet structure and function. Clinical laboratory science. 2015 Apr 1;28(2):125. DOI:10.29074/ascls.28.2.125.; Sang Y, Roest M, de Laat B, de Groot PG, Huskens D. Interplay between platelets and coagulation. Blood reviews. 2021 Mar 1;46:100733. DOI:10.1016/j.blre.2020.100733.; Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Feb 9;77(5):629–658. DOI:10.1016/j.jacc.2020.09.011.; Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017 Sep;102(3):397–404. DOI:10.1002/cpt.668.; Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23;375(9711):283–93. DOI:10.1016/S0140-6736(09)62191-7.; Меситская Д.Ф., Никитина Ю.М., Копылов Ф.Ю., и др. Клинические и фармакогенетические факторы, влияющие на резистентность к клопидогрелу у пациентов, страдающих сердечнососудистыми заболеваниями. Клиническая медицина. 2015;93(2):40–6. [Mesitskaya DF, Nikitina YuM, Kopylov FYu, et al. Clinical and pharmacological factors influencing resistance to clopidogrel in patients with cardiovascular diseases. Klin. med. 2015;93(2):40–6. (In Russ.)].; Harmsze A, van Werkum JW, Bouman HJ, et al. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics. 2010 Jan;20(1):18–25. DOI:10.1097/FPC.0b013e328333dafe.; Yu C, Yan Q, Fu C, et al. CYP4F2 genetic polymorphisms are associated with coronary heart disease in a Chinese population. Lipids Health Dis. 2014 May 20;13:83. DOI:10.1186/1476-511X-13-83.; Iqbal J, Sumaya W, Tatman V, et al. Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. Euro Intervention. 2013 May 20;9(1):62–9. DOI:10.4244/EIJV9I1A10.; Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009 Oct 20;54(17):1609–16. DOI:10.1016/j.jacc.2009.04.053.; Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575. Erratum in: Eur Heart J. 2021 May 14;42(19):1908. Erratum in: Eur Heart J. 2021 May 14;42(19):1925. Erratum in: Eur Heart J. 2021 May 13; PMID: 32860058.; Hurst NL, Nooney VB, Raman B, et al. Clopidogrel "resistance": pre- vs post-receptor determinants. Vascul Pharmacol. 2013 Nov-Dec;59(5-6):152–61. DOI:10.1016/j.vph.2013.10.002.; Pereira NL, Rihal CS, So DYF, et al. Clopidogrel Pharmacogenetics. Circ Cardiovasc Interv. 2019 Apr;12(4):e007811. DOI:10.1161/CIRCINTERVENTIONS.119.007811.; Verma SS, Bergmeijer TO, Gong L, et al. Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clin Pharmacol Ther. 2020 Nov;108(5):1067– 1077. DOI:10.1002/cpt.1911.; Gremmel T, Steiner S, Seidinger D, et al. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. Transl Res. 2013 May;161(5):421–9. DOI:10.1016/j.trsl.2012.12.015.; Kazi DS, Garber AM, Shah RU, et al. Cost-effectiveness of genotypeguided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med. 2014 Feb 18;160(4):221–32. DOI:10.7326/M13-1999.; Seo SM, Choo EH, Koh YS, et al. High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart. 2011 Dec;97(23):1943–50. DOI:10.1136/hrt.2011.225466.; Niessner A, Hofmann R, Kypta A, et al. Low high-density lipoprotein cholesterol predicts cardiovascular events after carotid stenting: a long-term survey. J Thromb Haemost. 2007 May;5(5):950–4. DOI:10.1111/j.1538-7836.2007.02451.x.

Διαθεσιμότητα: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/274
https://doi.org/10.37489/2588-0527-2023-1-46-55

Pharmacoeconomic analysis of personalized antiplatelet therapy in patients with acute coronary syndromer ; Фармакоэкономический анализ персонализированной антиагрегантной терапии пациентов с острым коронарным синдромом

Συγγραφείς: M. A. Abdullaev, B. I. Kantemirova, E. N. Chernysheva, М. А. Абдуллаев, Б. И. Кантемирова, Е. Н. Чернышева

Πηγή: Pharmacogenetics and Pharmacogenomics; № 1 (2022); 53-62 ; Фармакогенетика и фармакогеномика; № 1 (2022); 53-62 ; 2686-8849 ; 2588-0527

Θεματικοί όροι: полиморфизм гена CYP2C19, pharmacoeconomics, antiplatelet drugs, clopidogrel, CYP2C19 gene polymorphism, фармакоэкономика, антиагреганты, клопидогрел

Περιγραφή αρχείου: application/pdf

Relation: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/245/237; Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE. The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. Clin Pharmacol Ther. 2020 Jan;107(1):171–175. DOI:10.1002/cpt.1651; Dong OM, Wheeler SB, Cruden G, Lee CR, Voora D, Dusetzina SB, Wiltshire T. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. Value Health. 2020 Jan;23(1):61–73. DOI:10.1016/j.jval.2019.08.002; Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, Kisor DF, Limdi NA, Lee YM, Scott SA, Hulot JS, Roden DM, Gaedigk A, Caudle KE, Klein TE, Johnson JA, Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022 Nov;112(5):959–967. DOI:10.1002/cpt.2526; Чернов А. А., Мирзаев К. Б., Сычёв Д. А. Первый мета-анализ отечественных фармакогенетических исследований клопидогрела. Фармакогенетика и фармакогеномика. 2015;(2):19–23. [Chernov АА, Mirzaev KB, Sychev DA. The first meta-analysis of domestic pharmacogenetic studies of clopidogrel. Farmakogenetika i farmakogenomika = Pharmacogenetics and pharmacogenomics. 2015;(2):19–23. (In Russ).].; Patel V, Lin FJ, Ojo O, Rao S, Yu S, Zhan L, Touchette DR. Costutility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharm Pract (Granada). 2014 Jul;12(3):438. DOI:10.4321/s1886-36552014000300007; Borse MS, Dong OM, Polasek MJ, Farley JF, Stouffer GA, Lee CR. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. Pharmacogenomics. 2017 Aug;18(12):1155–1166. DOI:10.2217/pgs-2017-0075; Fu Y, Zhang XY, Qin SB, Nie XY, Shi LW, Shao H, Liu J. Costeffectiveness of CYP2C19 LOF-guided antiplatelet therapy in Chinese patients with acute coronary syndrome. Pharmacogenomics. 2020 Jan;21(1):33–42. DOI:10.2217/pgs-2019-0050; Wang Y, Yan BP, Liew D, Lee VWY. Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome. Pharmacogenomics J. 2018 Jan;18(1):113–120. DOI:10.1038/tpj.2016.94; Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J. 2017 Oct;17(5):395–402. DOI:10.1038/tpj.2017.21; Барышева В. О. Оценка рациональности применения фармакогенетического тестирования на клопидогрел при стентировании. Медицинская наука и образование Урала. 2016;17(2):116–119. [Barysheva VO. Preceding stenting clopidogrel pharmacogenetic testing rationality еvaluation. Medical science and education in the Urals. 2016;17(2):116–119. (In Russ).].; Сычёв Д. А., Шуев Г. Н., Торбенков Е. С., Адриянова М. А. Персонализированная медицина: взгляд клинического фармаколога. Consilium Medicum. 2017;19(1):61–68. [Sychev DA, Shuev GN, Torbenkov ES, Adrijanova MА. Personalized medicine: clinical pharmacologist’s opinion. Consilium Medicum. 2017;19(1):61–68. (In Russ).].; Мирзаев К. Б., Федоринов Д. С., Иващенко Д. В., Сычёв Д. А. Мультиэтнический анализ кардиологических фармакогенетических маркеров генов цитохрома Р450 и мембранных транспортёров в российской популяции. Рациональная Фармакотерапия в Кардиологии. 2019;15(3):393–406. [Mirzaev KB, Fedorinov DS, Ivashchenko DV, Sychev DA. Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome p450 and Membrane Transporters Genes in the Russian Population. Rational Pharmacotherapy in Cardiology. 2019;15(3):393–406. (In Russ).]. DOI:10.20996/1819-6446-2019-15-3-393-406; Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, Lerman A, Hasan A, Iturriaga E, Fu YP, Geller N, Bailey K, Farkouh ME. Clopidogrel Pharmacogenetics. Circ Cardiovasc Interv. 2019 Apr;12(4):e007811. DOI:10.1161/CIRCINTERVENTIONS.119.007811; Brown SA, Pereira N. Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. J Pers Med. 2018 Jan 30;8(1):8. DOI:10.3390/jpm8010008; Кантемирова Б. И., Тимофеева Н. В., Сычёв Д. А. и др. Сравнительное изучение полиморфизма гена CYP2C19 у детей, проживающих в Астраханском регионе. Астраханский медицинский журнал. 2011;6(3):136–42. [Kantemirova BI, Timofeeva NV, Sychev DA, et al. A comparative study of CYP2C19 gene polymorphism in children living in the Astrakhanian region. Astrakhan Medical Journal. 2011;6(3):136–142. (In Russ).].; Абдуллаев М. А., Кантемирова Б. И., Орлова Е. А. и др. Фармакоэкономические аспекты персонализированного подхода в лечении пациентов с острым коронарным синдромом: региональный анализ. Международный научно-исследовательский журнал. 2022;6-2(120):156–159. [Abdullaev MA, Kantemirova BI, Orlova EA, et al. Pharmacoeconomic aspects of personalized treatment of patients suffering from acute coronary syndrome: regional analysis. International Research Journal. 2022; 6-2(120):156–159. (In Russ).]. DOI:10.23670/IRJ.2022.120.6.060; Ягудина Р. И., Куликов А. Ю., Метелкин И. А. Методология анализа «затраты-эффективность» при проведении фармакоэкономических исследований. Фармакоэкономика. 2012;5(4):3–8. [Yagudina RI, Kulikov AYu, Metelkin IA. Methodology of cost-effectiveness analysis in pharmacoeconomics. Farmakoekonomika. 2012;5(4):3–8. (In Russ).].; Джалалов С. Ч., Джалалова Д. Х., Стюарт Х. Д. Интерпретация результатов оценки медицинских технологий. Медицинские технологии. Оценка и выбор. 2014;4(18):19–28. [Djalalov SCh, Djalalova DH, Hoch DS. Interpreting the Results of Health Technology Assessment. Medical Technologies. Assessment and Choice. 2014;4(18):19–28. (In Russ).].; Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001–2015. DOI:10.1056/NEJMoa0706482; Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045–1057. DOI:10.1056/NEJMoa0904327; Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23;375(9711):283–293. DOI:10.1016/S0140-6736(09)62191-7; Bavishi C, Panwar S, Messerli FH, Bangalore S. Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome. Am J Cardiol. 2015 Sep 1;116(5):809–817. DOI:10.1016/j.amjcard.2015.05.058; Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22;360(4):354–362. DOI:10.1056/NEJMoa0809171; Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009 May 19;119(19):2553–2560. DOI:10.1161/CIRCULATIONAHA.109.851949; Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost. 2010 Aug;8(8):1678– 1684. DOI:10.1111/j.1538-7836.2010.03923.x; Song YY, Lu Y. Decision tree methods: applications for classification and prediction. Shanghai Arch Psychiatry. 2015 Apr 25;27(2):130–135. DOI:10.11919/j.issn.1002-0829.215044; Ягудина Р. И., Куликов А. Ю., Серпик В. Г. Дисконтирование при проведении фармакоэкономических исследований. Фармакоэкономика. 2009;2(4):10–13. [Yagudina RI, Kulikov AYu, Serpik VG. Discounting for pharmacoeconomic evaluation. Pharmacoeconomics. 2009;2(4):10–13. (In Russ).].; Эрлих А. Д., Грацианский Н. А. Российский регистр острого коронарного синдрома «РЕКОРД-3». Характеристика пациентов и лечение до выписки из стационара. Кардиология. 2016;4:16–24. [Erlikh AD, Gratsiansky NA. Registry of acute coronary syndromes “RECORD-3”. Characteristics of patients and treatment during initial hospitalization. Kardiologiia. 2016;4:16–24. (In Russ).]. DOI:10.18565/cardio.2016.4.16-24; Kazi DS, Garber AM, Shah RU, Dudley RA, Mell MW, Rhee C, Moshkevich S, Boothroyd DB, Owens DK, Hlatky MA. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med. 2014 Feb 18;160(4):221–232. DOI:10.7326/M13-1999; Kim K, Touchette DR, Cavallari LH, Ardati AK, DiDomenico RJ. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome. Cardiovasc Drugs Ther. 2019 Oct;33(5):533–546. DOI:10.1007/s10557-019-06896-8

Διαθεσιμότητα: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/245
https://doi.org/10.37489/2588-0527-2022-1-53-62

Comprehensive Approach to Developing Baseline Reference Ranges for Platelet Function ; Комплексный подход к разработке референсных показателей для оценки функции тромбоцитов на начальном этапе исследования

Συγγραφείς: Olga B. Gordeeva, Maria S. Karaseva, Vasily A. Lastovka, Nato D. Vashakmadze, Margarita A. Soloshenko, Gregory V. Revunenkov, Kirill A. Valyalov, Viktor V. Altunin, О. Б. Гордеева, М. С. Карасева, В. А. Ластовка, Н. Д. Вашакмадзе, М. А. Солошенко, Г. В. Ревуненков, К. А. Валялов, В. В. Алтунин

Πηγή: Pediatric pharmacology; Том 20, № 2 (2023); 102–111 ; Педиатрическая фармакология; Том 20, № 2 (2023); 102–111 ; 2500-3089 ; 1727-5776

Θεματικοί όροι: агрегометр, aggregation, reference ranges, hemostasis, antiaggregants, children, thrombosis, trombocytopathya, aggregometer, агрегация, референсные интервалы, гемостаз, антиагреганты, дети, тромбоз, тромбоцитопатия

Περιγραφή αρχείου: application/pdf

Relation: https://www.pedpharma.ru/jour/article/view/2280/1471; Мазуров А.В. Физиология и патология тромбоцитов: монография. — М.: Литтерра; 2011. — 456 с.; Свешникова А.Н., Якушева А.А. Рябых О.Е. и др. Современные представления о регуляции тромбоцитарного гемостаза // Креативная кардиология. — 2018. — Т. 12. — № 3. — С. 260–274. — doi: https://doi.org/10.24022/1997-3187-201812-3-260-274; Васина Л.В., Петрищев Н.Н., Власов Т.Д. Эндотелиальная дисфункция и ее основные маркеры // Регионарное кровообращение и микроциркуляция. — 2017. — Т. 16. — № 1. — С. 4–15. — doi: https://doi.org/10.24884/1682-6655-201716-1-4-15; Савченко А.П., Медведев И.Н. Механизмы функционирования тромбоцитарного гемостаза // Фундаментальные исследования. — 2009. — № 10. — С. 28–30.; Карахалис Н.Б., Ефимочкин Г.А., Шадрин А.К., Синьков С.В. Антитромботическая терапия у детей // Анестезиология и реаниматология. — 2018. — Т 63. — № 1. — С. 46–55. — doi: https://doi.org/10.18821/0201-7563-2018-63-1-46-55; CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory: Approved Guideline. 3rd ed. CLSI document C28-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.; C LSI. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays: Approved Guideline, 5th ed. CLSI document H21-A5. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.; ГОСТ Р 15195-2006 «Лабораторная медицина. Требования к лабораториям референтных изменений». Дата введения 01.01.2008. Доступно по: https://docs.cntd.ru/document/1200053110. Ссылка активна на 17.09.2022.; Г ОСТ Р 53022.1-2008 «Технологии лабораторные клинические. Обеспечение качества клинических лабораторных исследований. Часть 4. Правила ведения преаналитического этапа». Дата введения 01.01.2010. Доступно по: https://docs.cntd.ru/document/1200069395. Ссылка активна на 17.09.2022.; Детская гематология: клинические рекомендации / под ред. А.Г. Румянцева, А.А. Масчана, Е.В. Жуковской. — М.: ГЭОТАРМедиа; 2015. — 656 с.; Ling LQ, Liao J, Niu Q, et al. Evaluation of an automated light transmission aggregometry. Platelets. 2017;28(7):712–719. doi: https://doi.org/10.1080/09537104.2016.1265923; Петрова О.В., Шашин С.А., Тарасов Д.Г. Референтные значения агрегации тромбоцитов при исследовании импедансным методом с аденозиндифосфорной кислотой на агрегометре Multiplate // Современные технологии в медицине. — 2016. — Т. 8. — № 3. — С. 100–104. — doi: https://doi.org/10.17691/stm2016.8.3.11; NCCLS. How to Define and Determine Reference Intervals in the Clinical Laboratory: Approved Guideline. 2nd ed. NCCLS document C28-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2000.; H alimeh S, Angelis G, Sander A, et al. Multiplate® Whole Blood Impedance Point of Care Aggregometry Preliminary Reference Values in Healthy Infants, Children and Adolescents. Klin Padiatr. 2010;222(3):158–163. doi: https://doi.org/10.1055/s-0030-1249081; Ковальчук Ю.П., Кадинская М.И., Пименов М.С., Ефимова И.Ю. Определение референсных значений для анализа агрегации тромбоцитов в автоматическом режиме на анализаторе Sysmex CS-5100 // Медицинский алфавит. — 2021. — № 13. —; С. 42–46. — doi: https://doi.org/10.33667/2078-5631-2021-1342-46; Platton S, McCormick Á, Bukht M, et al. A multicenter study to evaluate automated platelet aggregometry on Sysmex CS-series coagulation analyzers-preliminary findings. Res Pract Thromb Haemost. 2018;2(4):778–789. doi: https://doi.org/10.1002/rth2.12140; Отто Н.Ю., Сагитова Г.Р., Ледяев М.Я. и др. Тромбозы у детей (клинические случаи) // Вестник Волгоградского государственного медицинского университета. — 2020. — № 2. — С. 182–184. — doi: https://doi.org/10.19163/1994-94802020-2(74)-182-184; Online Mendelian Inheritance in Man (OMIM). In: National Library of Medicine. 15 Sep 2022. Available online https://www.ncbi.nlm.nih.gov/omim. Accessed on September 16, 2022.; Мансурова Д.А., Жунуспекова А.С., Каражанова Л.К. Референсные значения агрегации тромбоцитов у здоровых лиц // Клиническая лабораторная диагностика. — 2018. — Т. 63. — № 9. — С. 549–552. — doi: https://doi.org/10.18821/08692084-2018-63-9-549-552; https://www.pedpharma.ru/jour/article/view/2280

Διαθεσιμότητα: https://www.pedpharma.ru/jour/article/view/2280
https://doi.org/10.15690/pf.v20i2.2530

Antithrombotic therapy in COVID-19 patients ; Антитромботическая терапия у пациентов с COVID-19

Συγγραφείς: E. V. Slukhanchuk, V. O. Bitsadze, J. Kh. Khizroeva, M. V. Tretyakova, A. S. Shkoda, D. V. Blinov, V. I. Tsibizova, Z. Jinbo, S. Sheena, S. Sсhulman, J.-K. Gris, I. Elalamy, A. D. Makatsariya, Е. В. Слуханчук, В. О. Бицадзе, Д. Х. Хизроева, М. В. Третьякова, А. С. Шкода, Д. В. Блинов, В. И. Цибизова, Ч. Цзиньбо, С. Шина, С. Шульман, Ж.-К. Гри, И. Элалами, А. Д. Макацария

Πηγή: Obstetrics, Gynecology and Reproduction; Vol 16, No 6 (2022); 718-731 ; Акушерство, Гинекология и Репродукция; Vol 16, No 6 (2022); 718-731 ; 2500-3194 ; 2313-7347

Θεματικοί όροι: COVID-19, severe acute respiratory syndrome, SARS-CoV-2, antithrombotic therapy, antiaggregants, anticoagulants, тяжелый острый респираторный синдром, антитромботическая терапия, антиагреганты, антикоагулянты

Περιγραφή αρχείου: application/pdf

Relation: https://www.gynecology.su/jour/article/view/1521/1072; Schulman S., Sholzberg M., Spyropoulos A.C. et al. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost. 2022;20(10):2214–25. https://doi.org/10.1111/jth.15808.; Spyropoulos A.C., Connors J.M., Douketis J.D. et al. Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. J Thromb Haemost. 2022;20(10):2226–36. https://doi.org/10.1111/jth.15809.; Piazza G., Campia U., Hurwitz S. et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2060–72. https://doi.org/10.1016/j.jacc.2020.08.070.; Giannis D., Barish M.A., Goldin M. et al. Incidence of venous thromboembolism and mortality in patients with initial presentation of COVID-19. J Thromb Thrombolysis. 2021;51(4):897–901. https://doi.org/10.1007/s11239-021-02413-7.; Ilowite J., Lisker G., Greenberg H. Digital health technology and telemedicine-based hospital and home programs in pulmonary medicine during the COVID-19 pandemic. Am J Ther. 2021;28(2):e217–e223. https://doi.org/10.1097/MJT.0000000000001342.; Jnr B.A. Use of telemedicine and virtual care for remote treatment in response to COVID-19 pandemic. J Med Syst. 2020;44(7):132. https://doi.org/10.1007/s10916-020-01596-5.; Connors J.M., Brooks M.M., Sciurba F.C. et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA. 2021;326(17):1703–12. https://doi.org/10.1001/jama.2021.17272.; Gonzalez-Ochoa A.J., Raffetto J.D., Hernández A.G. et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. Thromb Haemost. 2021;121(7):944–54. https://doi.org/10.1055/a-1414-5216.; Hozayen S.M., Zychowski D., Benson S. et al. Outpatient and inpatientanticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. EClinicalMedicine. 2021;41:101139. https://doi.org/10.1016/j.eclinm.2021.101139.; Flam B., Wintzell V., Ludvigsson J.F. et al. Direct oral anticoagulant use and risk of severe COVID-19. J Intern Med. 2021;289(3):411–9. https://doi.org/10.1111/joim.13205.; Rivera-Caravaca J.M., Buckley B.J., Harrison S.L. et al. Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. Thromb Res. 2021;205:1–7. https://doi.org/10.1016/j.thromres.2021.06.014.; Kleindorfer D.O., Towfighi A., Chaturvedi S. et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364–e467. https://doi.org/STR.0000000000000375.; Rentsch C.T., Beckman J.A., Tomlinson L. et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ. 2021;372:n311. https://doi.org/10.1136/bmj.n311.; Richardson S., Hirsch J.S., Narasimhan M. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–9. https://doi.org/10.1001/jama.2020.6775.; Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.; Tritschler T., Mathieu M.-E., Skeith L. et al. Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. J Thromb Haemost. 2020;18(11):2958–67. https://doi.org/10.1111/jth.15094.; ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Patrick R Lawler P.R., Goligher E.C., Berger J.S. et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021;385(9):790–802. https://doi.org/10.1056/NEJMoa2105911.; Spyropoulos A.C., Goldin M., Giannis D. et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612–20. https://doi.org/10.1001/jamainternmed.2021.6203.; Sholzberg M., Tang G.H., Rahhal H. et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:n2400. https://doi.org/10.1136/bmj.n2400.; Battistoni I., Francioni M., Morici N. et al. Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes. J Cardiovasc Med (Hagerstown). 2022;23(4):264–71. https://doi.org/10.2459/JCM.0000000000001284.; Cohen S.L., Gianos E., Barish M.A. et al. Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients. Thromb Haemost. 2021;121(8):1043–53. https://doi.org/10.1055/a-1366-9656.; Di Castelnuovo A., Costanzo S., Antinori A. et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study. Thromb Haemost. 2021;121(8):1054–65. https://doi.org/10.1055/a-1347-6070.; Ionescu F., Jaiyesimi I., Petrescu I. et al. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis. Eur J Haematol. 2021;106(2):165–74. https://doi.org/10.1111/ejh.13533.; Sholzberg M., da Costa B.R., Tang G.H. et al. Randomized trials of therapeutic heparin for COVID-19: a meta-analysis. Res Pract Thromb Haemost. 2021;5(8):e12638. https://doi.org/10.1002/rth2.12638.; Gonzalez-Porras J.R., Belhassen-Garcia M., Lopez-Bernus A. et al. Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study. Sao Paulo Med J. 2021;140(1):123–33. https://doi.org/10.1590/1516-3180.2021.0098.R1.08062021.; Meizlish M.L., Goshua G., Liu Y. et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity scorematched analysis. Am J Hematol. 2021;96(4):471–9. https://doi.org/10.1002/ajh.26102.; Morici N., Podda G., Birocchi S. et al. Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. Eur J Clin Invest. 2022;52(5):e13735. https://doi.org/10.1111/eci.13735.; Smadja D.M., Bonnet G., Gendron N. et al. Intermediate- vs. standarddose prophylactic anticoagulation in patients with COVID-19 admitted in medical ward: A propensity score-matched cohort study. Front Med (Lausanne). 2021;8:747527. https://doi.org/10.3389/fmed.2021.747527.; Lopes R.D., de Barros E. Silva P.G.M., Furtado R.H.M. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021;397(10291):2253–63. https://doi.org/10.1016/S0140-6736(21)01203-4.; RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10320):143–51. https://doi.org/10.1016/S0140-6736(21)01825-0.; Berger J.S., Kornblith L.Z., Gong M.N.et al. Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalized patients with COVID-19: a randomized clinical trial. JAMA. 2022;327(3):227–36. https://doi.org/10.1001/jama.2021.23605.; Shen L., Qiu L., Liu D. et al. The association of low molecular weight heparin use and in-hospital mortality among patients hospitalized with COVID-19. Cardiovasc Drugs Ther. 2022;36(1):113–20. https://doi.org/10.1007/s10557-020-07133-3.; Poli D., Antonucci E., Ageno W. et al. Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register. Intern Emerg Med. 2022;17(4):1013–21. https://doi.org/10.1007/s11739-021-02891-w.; Zinellu A., Paliogiannis P., Carru C., Mangoni A.A. INR and COVID-19 severity and mortality: A systematic review with meta-analysis and metaregression. Adv Med Sci. 2021;66(2):372–80. https://doi.org/10.1016/j.advms.2021.07.009.; Fumagalli S., Trevisan C., Del Signore S. et al. COVID-19 and atrial fibrillation in older patients: does oral anticoagulant therapy provide a survival benefit? – An insight from the GeroCovid registry. Thromb Haemost. 2022;122(1):105–12. https://doi.org/10.1055/a-1503-3875.; Protasiewicz M., Reszka K., Kosowski W. et al. Anticoagulation prior to COVID-19 infection has no impact on 6 months mortality: A propensity score-matched cohort study. J Clin Med. 2022;11(2):352. https://doi.org/10.3390/jcm11020352.; Gozzo L., Viale P., Longo L. et al. The potential role of heparin in patients with COVID-19: beyond the anticoagulant effect. A review. Front Pharmacol. 2020;11:1307. https://doi.org/10.3389/fphar.2020.01307.; RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10320):143–51. https://doi.org/10.1016/S2213-2600(21)00435-5.; Steffel J., Verhamme P., Potpara T.S.et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–93. https://doi.org/10.1093/eurheartj/ehy136.; Foerster K.I., Hermann S., Mikus G., Haefeli W.E. Drug–drug interactions with direct oral anticoagulants. Clin Pharmacokinet. 2020;59(8):967–80. https://doi.org/10.1007/s40262-020-00879-x.; Cuker A., Tseng E.K., Nieuwlaat R. et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Adv. 2022;6(2):664–71. https://doi.org/10.1182/bloodadvances.2021005945.; Robinson S., Longmuir K., Pavord S. Haematology of pregnancy. Medicine. 2017;45(4):251–5. https://doi.org/10.1016.j.mpmed.2017.01.002.; D’Souza R., Malhamé I., Teshler L. et al. A critical review of the pathophysiology of thrombotic complications and clinical practice recommendations for thromboprophylaxis in pregnant patients with COVID-19. Acta Obstet Gynecol Scand. 2020;99(9):1110–20. https://doi.org/10.1111/aogs.13962.; Servante J., Swallow G., Thornton J.G. et al. Haemostatic and thromboembolic complications in pregnant women with COVID-19: a systematic review and critical analysis. BMC Pregnancy Childbirth. 2021;21(1):1–14. https://doi.org/10.1186/s12884-021-03568-0.; Daru J., White K., Hunt B.J. COVID-19, thrombosis and pregnancy.Thromb Update. 2021;5:100077. https://doi.org/10.1016/j.tru.2021.100077.; Lee Y.R., Blanco D.D. Efficacy of standard dose unfractionated heparin for venous thromboembolism prophylaxis in morbidly obese and non-morbidly obese critically ill patients. J Thromb Thrombolysis. 2017;44(3):386–91. https://doi.org/10.1007/s11239-017-1535-8.; Hendren N.S., De Lemos J.A., Ayers C. et al. Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation. 2021;143(2):135–44. https://doi.org/10.1161/CIRCULATIONAHA.120.051936.; Sawadogo W., Tsegaye M., Gizaw A., Adera T. Overweight and obesity as risk factors for COVID-19-associated hospitalisations and death: systematic review and meta-analysis. BMJ NutR Prev Health. 2022;5(1):10–8. https://doi.org/10.1136/bmjnph-2021-000375.; Hunt B.J. Hemostasis at extremes of body weight. Semin Thromb Hemost. 2018;44(7):632–9. https://doi.org/10.1055/s-0038-1661385.; Belančić A., Kresović A., Rački V. Potential pathophysiological mechanisms leading to increased COVID-19 susceptibility and severity in obesity. Obes Med. 2020;19:100259. https://doi.org/10.1016/j.obmed.2020.100259.; Wang T.-F., Milligan P.E., Wong C.A. et al. Efficacy and safety of highdose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost. 2014;111(1):88–93. https://doi.org/10.1160/TH13-01-0042.; He Z., Morrissey H., Ball P. Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients – Actual Weight-based vs Fixed. Crit Rev Oncol Hematol. 2017;113:191–4. https://doi.org/10.1016/j.critrevonc.2017.03.022.; Liu Y., Du X., Chen J. et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81(1):e6–e12. https://doi.org/10.1016/j.jinf.2020.04.002.; Miranda S., Le Cam-Duchez V., Benichou J. et al. Adjusted value of thromboprophylaxis in hospitalized obese patients: a comparative study of two regimens of enoxaparin: the ITOHENOX study. Thromb Res. 2017;155:1–5. https://doi.org/10.1016/j.thromres.2017.04.011.; INSPIRATION Investigators; Sadeghipour P., Talasaz A., Rashidi F. et al. Eeffect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021;325(16):1620–30. https://doi.org/10.1001/jama.2021.4152.; Moores L.K., Tritschler T., Brosnahan S. et al. Thromboprophylaxis in patients with COVID-19: a brief update to the CHEST guideline and expert panel report. Chest. 2022;162(1):213–25. https://doi.org/10.1016/j.chest.2022.02.006.; Cohoon K.P., Mahé G., Tafur A.J., Spyropoulos A.C. Emergence of institutional antithrombotic protocols for coronavirus 2019. Res Pract Thromb Haemost. 2020;4(4):510–7. https://doi.org/10.1002/rth2.12358.; Stevens S.M., Woller S.C., Kreuziger L.B. et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545–e608. https://doi.org/10.1016/j.chest.2021.07.055.; Wang Y., Zhu F., Wang C. et al. Children hospitalized with severe COVID-19 in Wuhan. Pediatr Infect Dis J. 2020;39(7):e91–e94. https://doi.org/10.1097/INF.0000000000002739.; Cruz A.T., Zeichner S.L. COVID-19 in children: initial characterization of the pediatric disease. Pediatrics. 2020;145(6):e20200834. https://doi.org/10.1542/peds.2020-0834.; Feldstein L.R., Rose E.B., Horwitz S.M. et al. Multisystem inflammatory syndrome in US children and adolescents. N Engl J Med. 2020;383(4):334–46. https://doi.org/10.1056/NEJMoa2021680.; Goldenberg N.A., Sochet A., Albisetti M. et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. 2020;18(11):3099–105. https://doi.org/10.1111/jth.15073.; Sochet A.A., Morrison J.M., Jaffray J. et al. Enoxaparin thromboprophylaxis in children hospitalized for COVID-19: A phase 2 trial. Pediatrics. 2022;150(1):e2022056726. https://doi.org/10.1542/peds.2022-056726.; Shafiee M.A., Hosseini S.F., Mortazavi M. et al. Anticoagulation therapy in COVID-19 patients with chronic kidney disease. J Res Med Sci. 2021;26:63. https://doi.org/10.4103/jrms.JRMS_875_20.; Fernandez P., Saad E.J., Barrionuevo A.D. et al. The incidence, risk factors and impact of acute kidney injury in hospitalized patients due to COVID-19. Medicina (B Aires). 2021;81(6):922–30.; Stevens J.S., Velez J.C.Q., Mohan S. Continuous renal replacement therapy and the COVID pandemic. Semin Dial. 2021;34(6):561–6. https://doi.org/10.1111/sdi.12962.; Arnold F., Westermann L., Rieg S. et al. Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study. BMC Nephrol. 2020;21(1):486. https://doi.org/10.1186/s12882-020-02150-8.; Billett H., Reyes-Gil M., Szymanski J. et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin and apixaban on mortality. Thromb Haemost. 2020;120(12):1691–9. https://doi.org/10.1055/s-0040-1720978.; Attallah N., Gupta S., Madhyastha R. et al. Anticoagulation in COVID-19 patients requiring continuous renal replacement therapy. Anaesth Crit Care Pain Med. 2021;40(3):100841. https://doi.org/10.1016/j.accpm.2021.100841.; Schünemann H.J., Cushman M., Burnett A.E. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198–225. https://doi.org/10.1182/bloodadvances.2018022954.; PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group; Cook D., Meade M., Guyatt G. et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364(14):1305–14. https://doi.org/10.1056/NEJMoa1014475.; Perepu U.S., Chambers I., Wahab A. et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multicenter, open-label, randomized controlled trial. J Thromb Haemost. 2021;19(9):2225–34. https://doi.org/10.1111/jth.1545.; REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher E.C., Bradbury C.A., McVerry B.J. et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777–89. https://doi.org/10.1056/NEJMoa2103417.; REMAP-CAP Writing Committee for the REMAP-CAP Investigators; Bradbury C.A., Lawler P.R., Stanworth S.J. et al. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1247–59. https://doi.org/10.1001/jama.2022.2910.; Bikdeli B., Talasaz A.H., Rashidi F. et al. Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial. Thromb Haemost. 2022;122(1):131–41. https://doi.org/10.1055/a-1485-2372.; Oliynyk O., Barg W., Slifirczyk A. et al. Comparison of the effect of unfractionated heparin and enoxaparin sodium at different doses on the course of COVID-19-associated coagulopathy. Life (Basel). 2021;11()10:1032. https://doi.org/10.3390/life11101032.; El-Ghiaty M.A, Shoieb S.M., El-Kadi A.O. Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms. Med Hypotheses. 2020;144:110033. https://doi.org/10.1016/j.mehy.2020.110033.; Vincent J.-L., Levi M., Hunt B.J. Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respir Med. 2021;10(2):214–20. https://doi.org/10.1016/S2213-2600(21)00455-0.; Roberts L.N., Whyte M.B., Georgiou L. et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020;136(11):1347–50. https://doi.org/10.1182/blood.2020008086.; Rashidi F., Barco S., Kamangar F. et al. Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study. Thromb Res. 2021;198:135–8. https://doi.org/10.1016/j.thromres.2020.12.001.; Patell R., Bogue T., Koshy A. et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020;136(11):1342–6. https://doi.org/10.1182/blood.2020007938.; Giannis D., Allen S.L., Tsang J. et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. 2021;137(20):2838–47. https://doi.org/10.1182/blood.2020010529.; Lui D.T.W., Li Y.K., Lee C.H. et al. A prospective study of the impact of glycaemic status on clinical outcomes and anti-SARS-CoV-2 antibody responses among patients with predominantly non-severe COVID-19. Diabetes Res Clin Pract. 2022;185:109232. https://doi.org/10.1016/j.diabres.2022.109232.; Chioh F.W., Fong S.-W., Young B.E. et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. Elife. 2021;10:e64909. https://doi.org/10.7554/eLife.6490.; Spyropoulos A.C., Cohen S.L., Gianos E. et al. Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. Res Pract Thromb Haemost. 2021;5(2):296–300. https://doi.org/10.1002/rth2.12486.; Goldin M., Lin S.K., Kohn N. et al. External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19. J Thromb Thrombolysis. 2021;52(4):1032–5. https://doi.org/10.1007/s11239-021-02504-5.; Ramacciotti E., Agati L.B., Calderaro D. et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399(10319):50–9. https://doi.org/10.1016/S0140-6736(21)02392-8.; https://www.gynecology.su/jour/article/view/1521

Διαθεσιμότητα: https://www.gynecology.su/jour/article/view/1521
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.370

Surface-enhanced Raman spectroscopy for searching pharmacodynamic predictors of response to antiplatelet therapy ; Использование спектроскопии гигантского комбинационного рассеяния для поиска фармакодинамических предикторов ответа на антиагрегантную терапию

Συγγραφείς: E. M. Moiseeva, V. V. Rafalskiy, A. N. Sokolov, A. Yu. Zyubin, Ya. A. Bychkova, I. G. Samusev, Е. М. Моисеева, В. В. Рафальский, А. Н. Соколов, А. Ю. Зюбин, Я. А. Бычкова, И. Г. Самусев

Συνεισφορές: Zyubin A.Yu. and Bychkova Ya.A. were supported at the expense of the Agreement with the Ministry of Education and Science of the Russian Federation No. 075-02-2023-934., А.Ю. Зюбин и Я.А. Бычкова были поддержаны за счет средств Соглашения с Министерством образования и науки РФ № 075-02-2023-934.

Πηγή: Siberian Journal of Clinical and Experimental Medicine; Том 38, № 3 (2023); 185-193 ; Сибирский журнал клинической и экспериментальной медицины; Том 38, № 3 (2023); 185-193 ; 2713-265X ; 2713-2927

Θεματικοί όροι: клопидогрел, antiplatelet agents, SERS-spectroscopy, pharmacokinetics, acetylsalicylic acid, clopidogrel, антиагреганты, ГКРС-спектроскопия, фармакокинетика, ацетилсалициловая кислота

Περιγραφή αρχείου: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/1873/850; https://www.sibjcem.ru/jour/article/view/1873/875; Естественное движение населения Российской Федерации. Федеральная служба государственной статистики. URL: https://rosstat.gov.ru/compendium/document/13269 (18.01.2023).; Стабильная ишемическая болезнь сердца: Клинические рекомендации. Российское кардиологическое общество. Российский кардиологический журнал. 2020;25(11):4076. DOI:10.15829/29/1560-4071-2020-4076.; Гончаров М.Д., Гринштейн Ю.И., Савченко А.А. Особенности продукции активных форм кислорода тромбоцитами и нейтрофилами в формировании недостаточного ответа на ацетилсалициловую кислоту у пациентов с ишемической болезнью сердца после операции коронарного шунтирования. Трансляционная медицина. 2022;9(1):12–28. DOI:10.18705/2311-449-2022-9-1-12-28.; Karunawan N.H., Pinzon R.T. Prevalence of aspirin and clopidogrel resistance in patients with recurrent ischaemic cerebrovascular disease. Eur. Cardiol. Feb. 2021;16:e72. DOI:10.15420/ecr.2021.16.PO16.; Ebrahimi P., Farhadi Z., Behzadifar M., Shabaninejad H., Abolghasem Gorji H., Taheri Mirghaed M. et al. Prevalence rate of laboratory defined aspirin resistance in cardiovascular disease patients: A systematic review and meta-analysis. Caspian J. Intern. Med. 2020;11(2):124–134. DOI:10.22088/cjim.11.2.124.; Guirgis M., Thompson P., Jansen S. Review of aspirin and clopidogrel resistance in peripheral arterial disease. J. Vasc. Surg. 2017;66(5):1576–1586. DOI:10.1016/j.jvs.2017.07.065.; Эверстова Т.Е., Николаева Т.Я. Проблемы резистентности к ацетилсалициловой кислоте в профилактике ишемического инсульта (обзор литературы). Сибирское медицинское обозрение. 2020;(3):47–53. DOI:10.20333/2500136-2020-3-47-53.; Pereira N.L., Rihal C.S., So D.Y.F., Rosenberg Y., Lennon R.J., Mathew V. et al. Clopidogrel pharmacogenetics. Circ. Cardiovasc. Interv. 2019;12(4):e007811. DOI:10.1161/CIRCINTERVENTIONS.119.007811.; Vardon-Bounes F., Garcia C., Piton A., Series J., Gratacap M.P., Poëtte M. et al. Evolution of platelet activation parameters during septic shock in intensive care unit. Platelets. 2022;33(6):918–925. DOI:10.1080/09537104.2021.2007873.; Khan H., Kanny O., Syed M.H., Qadura M. Aspirin resistance in vascular disease: A review highlighting the critical need for improved point-of-care testing and personalized therapy. Int. J. Mol. Sci. 2022;23(19):11317. DOI:10.3390/ijms231911317.; Wan H., Han W., Wu Z., Lie Z., Li D., Su S. Whole blood dynamic platelet aggregation counting and 1-year clinical outcomes in patients with coronary heart diseases treated with clopidogrel. Platelets. 2021;32(7):968–974. DOI:10.1080/09537104.2020.1817886.; Pocock S.J., McCormack V., Gueyffier F., Boutitie F., Fagard R.H., Boissel J.P. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323(7304):75–81. DOI:10.1136/bmj.323.7304.75.; Piao J., Yoo C., Kim S., Whang Y.W., Choi C.U., Shin S. Performance comparison of the PFA-200 and Anysis-200: Assessment of bleeding risk screening in cardiology patients. Clin. Hemorheol. Microcirc. 2021;79(3):445–454. DOI:10.3233/CH-211185.; Lordkipanidzé M., Hvas A.-M., Harrison P. Clinical Tests of Platelet Function. In: Platelets; 2019:593–608. [Internet]. URL: https://www.researchgate.net/topic/Platelets/publications (17.03.2023).; Zyubin A., Rafalskiy V., Tcibulnikova A., Moiseeva Е., Matveeva К., Tsapkova А. et al. Surface-enhanced Raman spectroscopy for antiplatelet therapy effectiveness assessment. Laser Physics Letters. 2020;17(4). DOI:10.1088/1612-202X/ab7be5.; Paniccia R., Priora R., Liotta A.A., Abbate R. Platelet function tests: a comparative review. Vasc. Health Risk Manag. 2015;11:133–148. DOI:10.2147/VHRM.S44469.; Рафальский В.В., Зюбин А.Ю., Моисеева Е.М., Самусев И.Г. Перспективы применения метода спектроскопии комбинационного рассеяния света (рамановской спектроскопии) в кардиологии. Кардиоваскулярная терапия и профилактика. 2020;19(1):70–77. DOI:10.15829/1728-8800-2020-1-2394.; Quarin S., Strobbia P. Recent advances towards point-of-care applications of surface-enhanced raman scattering sensing. Front. Chem. 2021;9:714113. DOI:10.3389/fchem.2021.714113.; Atkins C.G., Buckley K., Blades M.W., Turner R.F. Raman spectroscopy of blood and blood components. Applied spectroscopy. 2017;71(5):767–793. DOI:10.1177/0003702816686593.; Sang Y., Roest M., de Laat B., de Groot P.G., Huskens D. Interplay between platelets and coagulation. Blood Rev. 2021;46:100733. DOI:10.1016/j.blre.2020.100733.; https://www.sibjcem.ru/jour/article/view/1873

Διαθεσιμότητα: https://www.sibjcem.ru/jour/article/view/1873
https://doi.org/10.29001/2073-8552-2022-538

Перспективы Применения Ривароксабана В Лечении Пациентов С Хронической Ишемической Болезнью Сердца

Συγγραφείς: Тохировна, Бувамухамедова Насиба, Отаханович, Жаббаров Озимбай, Файзуллаевна, Мирзаева Гульчехра, Маматович, Рахматов Аваз

Πηγή: SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; Vol. 1 No. 7 (2022): AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI; 10-14 ; НАУЧНЫЙ ЖУРНАЛ ПРИКЛАДНЫХ И МЕДИЦИНСКИХ НАУК; Том 1 № 7 (2022): AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI; 10-14 ; 2181-3469

Θεματικοί όροι: хроническая ИБС, прогноз, эффективность и безопасность терапии, антиагреганты, ривароксабан

Περιγραφή αρχείου: application/pdf

Relation: https://sciencebox.uz/index.php/amaltibbiyot/article/view/4851/4376; https://sciencebox.uz/index.php/amaltibbiyot/article/view/4851

Διαθεσιμότητα: https://sciencebox.uz/index.php/amaltibbiyot/article/view/4851

Sneddon syndrome: A rare diagnosis ; Синдром Снеддона

Συγγραφείς: D. Yu. Andriyashkina, A. A. Kondrashov, N. А. Shostak, N. A. Demidova, D. V. Yudin, D. Yu. Kulakov, G. R. Avetisian, Д. Ю. Андрияшкина, А. А. Кондрашов, Н. А. Шостак, Н. А. Демидова, Д. В. Юдин, Д. Ю. Кулаков, Г. Р. Аветисян

Πηγή: Rheumatology Science and Practice; Vol 60, No 6 (2022); 630-637 ; Научно-практическая ревматология; Vol 60, No 6 (2022); 630-637 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: антиагреганты, recurrent strokes, acute cerebrovascular disease, livedo racemose, livedo reticularis, neuroectodermal syndrome, antiphospholipid syndrome, vasculopathy, anticoagulants, antiplatelets, рецидивирующие инсульты, острое нарушение мозгового кровообращения, сетчатое ливедо, нейрокожный синдром, антифосфолипидный синдром, васкулопатия, антикоагулянты

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3255/2250; Ehrmann S. Ein neues Gefassymptom bei Lues. Wien Med Wochenschr. 1907;(16):777-782.; Kimming J. Arteriolopathie: Livedo rasemosa. Dermatol Wochenschr. 1959;139:211.; Champion RH, Rook A. Cutaneous arteriolitis. Proc R Soc Med. 1960;53:568.; Sneddon IB. Cerebro-vascular lesions and livedo reticularis. Br J Dermatol. 1965;77:180-185. doi:10.1111/j.1365-2133.1965.tb14628.x; Rumpl E, Rumpl H. Recurrent transient global amnesia in a case with cerebrovascular lesions and livedo reticularis (Sneddon syndrome). J Neurol. 1979;221(2):127-131. doi:10.1007/BF00313110; Bottin L, Frances C, de Zuttere D, Boёlle PY, Muresan IP, Alamowitch S. Strokes in Sneddon syndrome without antiphospholipid antibodies. Ann Neurol. 2015;77(5):817-829. doi:10.1002/ana.24382; Zelger B, Sepp N, Stockhammer G, Dosch E, Hilty E, Ofner D, et al. Sneddon’s syndrome. A long-term follow-up of 21 patients. Arch Dermatol. 1993;129(4):437-447. doi:10.1001/archderm.129.4.437; Berciano J. Sneddon syndrome: Another Mendelian etiology of stroke. Ann Neurol. 1988;24(4):586-587. doi:10.1002/ana.410240422; Villaizán C, Ferrada MJ, Legarda I, Iriarte J, Narbona J, Martínez-Lage JM. Vasculopatía asociada a anticuerpos antifosfolípido. Síndrome de Sneddon en la niñez. Neurologia. 1995;10(1):41-45.; Francès C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore) 1999;78(4):209-219. doi:10.1097/00005792-199907000-00001; Bolayir E, Yilmaz A, Kugu N, Erdogan H, Akyol M, Akyuz A. Sneddon’s syndrome: Clinical and laboratory analysis of 10 cases. Acta Med Okayama. 2004;58(2):59-65. doi:10.18926/AMO/32100; Kume M. Imai H., Motegi M, Miura AB, Namura I. Sneddon’s syndrome (livedo racemosa and cerebral infarction) presenting psychiatric disturbance and shortening of fingers and toes. Intern Med. 1996;35(8):668-673. doi:10.2169/internalmedicine.35.668; Charles PD, Fenichel GM. Sneddon and antiphospholipid antibody syndromes causing bilateral thalamic infarction. Pediatr Neurol. 1994;10(3):262-263. doi:10.1016/0887-8994(94)90037-x; Szmyrka-Kaczmarek M, Daikeler T, Benz D, Koetter I. Familial inflammatory Sneddon’s syndrome – Case report and review of the literature. Clin Rheumatol. 2005;24(1):79-82. doi:10.1007/s10067-004-0981-9; Hademenos GJ, Alberts MJ, Awad I, Mayberg M, Shepard T, Jagoda A, et al. Advances in the genetics of cerebrovascular disease and stroke. Neurology. 2001;56(8):997-1008. doi:10.1212/wnl.56.8.997; Rebollo M, Val JF, Garijo F, Quintana F, Berciano J. Livedo reticularis and cerebrovascular lesions (Sneddon’s syndrome). Clinical, radiological and pathological features in eight cases. Brain. 1983;106(4):965-979. doi:10.1093/brain/106.4.965; Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911-920. doi:10.1056/NEJMoa1307361; Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): Updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38(5):569-578. doi:10.1007/s10875-018-0525-8; Wu S, Xu Z, Liang H. Sneddon’s syndrome: A comprehensive review of the literature. Orphanet J Rare Dis. 2014;9:215. doi:10.1186/s13023-014-0215-4; Daoud MS, Wilmoth GJ, Su WP, Pittelkow MR. Sneddon syndrome. Semin Dermatol. 1995;14(2):166-172. doi:10.1016/s1085-5629(05)80014-8; Schlez A, Lischka G, Schaumburg-Lever G, Ganter T, Jünger M. Raynaud symptoms as principal signs in a case of Sneddon’s syndrome. J Eur Acad Dermatol Venereol. 2001;15(4):365-366.; Heckmann JG, Lufti M. Images in clinical medicine. Angiomatosis associated with Sneddon’s syndrome. N Engl J Med. 2004;350(12):11. doi:10.1056/ENEJMicm020035; Lipsker D, Piette JC, JL, Maunoury L, Francès C. Annular atrophic lichen planus and Sneddon’s syndrome. Dermatology. 1997;195(4):402-403. doi:10.1159/000245999; Калашникова ЛА. Неврология антифосфолипидного синдрома. М.:Медицина;2003.; Tourbah A, Piette JC, Iba-Zizen MT, Lyon-Caen O, Godeau P, Francès C. The natural course of cerebral lesions in Sneddon syndrome. Arch Neurol. 1997;54(1):53-60. doi:10.1001/archneur.1997.00550130037013; Adair JC, Digre KB, Swanda RM, Hartshorne MF, Lee RR, Constantino TM, et al. Sneddon’s syndrome: A cause of cognitive decline in young adults. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(3):197-204.; Devuyst G, Sindic C, Laterre EC, Brucher JM. Neuropathological findings of a Sneddon’s syndrome presenting with dementia not preceded by clinical cerebrovascular events. Stroke. 1996;27(5): 1008-1010.; Wright RA, Kokmen E. Gradually progressive dementia without discrete cerebrovascular events in a patient with Sneddon’s syndrome. Mayo Clin Proc. 1999;74(1):57-61. doi:10.4065/74.1.57; Hsu FF, Chung KH. Psychosis with suicide attempt in Sneddon syndrome. Psychiatry Clin Neurosci. 2017;71(2):147-148. doi:10.1111/pcn.12489; Pauranik A, Parwani S, Jain S. Simultaneous bilateral central retinal arterial occlusion in a patient with Sneddon syndrome: Case history. Angiology. 1987;2(Pt 1):158-163. doi:10.1177/000331978703800211; Aggermann T, Haas P, Binder S. Central retinal vein occlusion as a possible presenting manifestation of Sneddon syndrome. J Neuroophthalmol. 2007;27(3):240-241. doi:10.1097/WNO.0b013e31814b259f; Насонов ЕЛ. Антифосфолипидный синдром. М.:Литтерра;2004.; Starmans NLP, van Dijk MR, Kappelle LJ, Frijns CJM. Sneddon syndrome: A comprehensive clinical review of 53 patients. J Neurol. 2021;268(7):2450-2457. doi:10.1007/s00415-021-10407-x; Besnier R, Frances C, Ankri A, Aiach M, Piette JC. Factor V Leiden mutation in Sneddon syndrome. Lupus. 2003;12(5):406-408. doi:10.1191/0961203303lu386sr; Donnet A, Khalil R, Terrier G, Koeppel MC, Njee BT, Aillaud MF. Cerebral infarction, livedo reticularis, and familial deficiency in antithrombin-III. Stroke. 1992;23(4):611-612.; Kalashnikova LA, Korczyn AD, Shavit S, Rebrova O, Reshetnyak T, Chapman J. Antibodies to prothrombin in patients with Sneddon’s syndrome. Neurology. 1999;53(1):223-225. doi:10.1212/wnl.53.1.223; Sayin R, Bilgili SG, Karadag AS, Tombul T. Sneddon syndrome associated with protein S deficiency. Indian J Dermatol Venereol Leprol. 2012;78(3):407. doi:10.4103/0378-6323.95483; Forchhammer S, Metzler G, Ghoreschi K. Long-term follow-up of early-onset Sneddon syndrome: A case report. JAAD Case Rep. 2018;4(9):880-882. doi:10.1016/j.jdcr.2018.08.008

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3255
https://doi.org/10.47360/1995-4484-2022-630-637

Analysis of the consumption volumes of antithrombotic drugs used for pharmacotherapy of atrial fibrillation in Saratov Region ; Анализ объемов потребления антитромботических препаратов, применяемых для фармакотерапии фибрилляции предсердий в Саратовской области

Συγγραφείς: А. V. Sokolov, О. V. Reshet’ko, А. В. Соколов, О. В. Решетько

Πηγή: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 14, No 4 (2021); 462-467 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 14, No 4 (2021); 462-467 ; 2070-4933 ; 2070-4909

Θεματικοί όροι: объемы потребления, anticoagulants, antiplatelet agents, consumption volumes, антикоагулянты, антиагреганты

Περιγραφή αρχείου: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/624/399; Björck S., Palaszewski B., Friberg L., Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013; 44 (1): 3103–8. https://doi.org/10.1161/STROKEAHA.113.002329.; Haim M., Hoshen M., Reges O., et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015; 4 (1): e001486. https://doi.org/10.1161/JAHA.114.001486.; Krijthe B.P., Kunst A., Benjamin E.J., et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013; 34 (35): 2746–51. https://doi.org/10.1093/eurheartj/eht280.; Conen D. Epidemiology of atrial fibrillation. Eur Heart J. 2018; 39 (16): 1323–4. https://doi.org/10.1093/eurheartj/ehy171.; Kirchhof P., Benussi S., Kotecha D., et al. Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Российский кардиологический журнал. 2017; 7: 7–86. https://doi.org/10.15829/1560-4071-2017-7-7-86.; Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation. 2010; 121 (7): e46–215. https://doi.org/10.1161/CIRCULATIONAHA.109.192667.; Wang G., Joo H., Tong X., George M.G. Hospital costs associated with atrial fibrillation for patients with ischemic stroke aged 18–64 years in the United States. Stroke. 2015; 46 (5): 1314–20. https://doi.org/10.1161/STROKEAHA.114.008563.; Fuster V., Rydén L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2006; 48 (4): 854–906. https://doi.org/10.1016/j.jacc.2006.07.009.; Бокерия Л.А., Ревишвили А.Ш., Оганов Р.Г. и др. Клинические рекомендации по диагностике и лечению пациентов с фибрилляцией предсердий. Вестник аритмологии. 2010; 59: 53–77.; Steffel J., Verhamme P., Potpara T.S., et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39 (16): 1330–93. https://doi.org/10.1093/eurheartj/ehy136.; Сулимов В.А., Голицын С.П., Панченко Е.П. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. URL: https://scardio.ru/content/Guidelines/FP_rkj_13.pdf (дата обращения 17.03.2021).; Camm A.J., Lip G.Y., De Caterina R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33 (21): 2719–47. https://doi.org/10.1093/eurheartj/ehs253.; Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. URL: http://webmed.irkutsk.ru/doc/pdf/af.pdf (дата обращения 17.03.2021).; Proietti M., Laroche C., Nieuwlaat R., et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: a comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018; 55: 28–34. https://doi.org/10.1016/j.ejim.2018.05.016.; Gadsbøll K., Staerk L., Fosbøl E.L., et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017; 38 (12): 899–906. https://doi.org/10.1093/eurheartj/ehw658.; Cowan J.C., Wu J., Hall M., et al. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018; 39 (32): 2975–83. https://doi.org/10.1093/eurheartj/ehy411.; Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009; 361 (12): 1139–51. https://doi.org/10.1056/NEJMoa0905561.; WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. URL: https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/ (дата обращения 23.03.2021).; Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011; 365 (11): 981–92. https://doi.org/10.1056/NEJMoa1107039.; Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011; 365 (10): 883–91. https://doi.org/10.1056/NEJMoa1009638.; Guelker J.E., Bufe A., Klues H., et al. Trends in atrial fibrillation and prescription of oral anticoagulants and embolic strokes in Germany. Cardiovasc Revasc Med. 2019; 20 (5): 399–402. https://doi.org/10.1016/j.carrev.2018.07.019.; Sepúlveda R.L., Anaya-Ordóñez S., García E.E., et al. DI-023 Utilisation study of oral anticoagulants (2008–2015) and bleeding due to anticoagulant treatment (2012–2015). Eur J Hosp Pharm. 2017; 24 (Suppl. 1): A122–3. https://doi.org/10.1136/ejhpharm-2017-000640.270.; https://www.pharmacoeconomics.ru/jour/article/view/624

Διαθεσιμότητα: https://www.pharmacoeconomics.ru/jour/article/view/624
https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.090

Drug-induced non-traumatic intracranial hemorrhage associated with the use of anticoagulants and antiplatelet agents ; Лекарственно-индуцированные нетравматические внутричерепные кровоизлияния, ассоциированные с применением антикоагулянтов и антиагрегантов

Συγγραφείς: O. D. Ostroumova, A. I. Listratov, T. M. Ostroumova, A. I. Kochetkov, D. A. Sychev, О. Д. Остроумова, А. И. Листратов, Т. М. Остроумова, А. И. Кочетков, Д. А. Сычев

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 6 (2022); 80-88 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 6 (2022); 80-88 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-6

Θεματικοί όροι: тромболитические препараты, intracranial hemorrhage, intracerebral hemorrhage, drug-induced intracerebral hemorrhage, drug-induced intracranial hemorrhage, anticoagulants, antiplatelet agents, thrombolytic drugs, внутричерепное кровоизлияние, внутримозговое кровоизлияние, лекарственно-индуцированное внутримозговое кровоизлияние, лекарственно-индуцированное внутричерепное кровоизлияние, антикоагулянты, антиагреганты

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1925/1481; Клинические рекомендации. Геморрагический инсульт. Минздрав России, Ассоциация нейрохирургов России, Всероссийское общество неврологов, Ассоциация анестезиологов и реаниматологов России, Ассоциация реабилитологов России. Пересмотр 2020 г. Доступно по ссылке: https://ruans.org/Text/Guidelines/hemorrhagic_stroke-2020.pdf (дата обращения 09.07.2022).; Парфенов ВА. Нарушения мозгового кровообращения. В кн.: Парфенов ВА, Яхно НН, Зиновьева ОЕ. Нервные болезни. Москва: ООО «Издательство «Медицинское информационное агентство»; 2021. С. 22-72.; Парфенов ВА, Кулеш АА. Цереброваскулярное заболевание с когнитивными нарушениями. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(9):121-30. doi:10.17116/jnevro2021121091121; Unnithan AKA, Mehta P. Hemorrhagic Stroke. [Updated 2022 Feb 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559173/; An SJ, Kim TJ, Yoon BW. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. J Stroke. 2017 Jan;19(1):3-10. doi:10.5853/jos.2016.00864; Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md: American Society of Health-System Pharmacists; 2018. P. 237-51.; Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005 Jul;36(7):1588-93. doi:10.1161/01.STR.0000170642.39876.f2; Liotta EM, Prabhakaran S. Warfarin-associated intracerebral hemorrhage is increasing in prevalence in the United States. J Stroke Cerebrovasc Dis. 2013 Oct;22(7):1151-5. doi:10.1016/j.jstrokecerebrovasdis.2012.11.015; Franke CL, de Jonge J, van Swieten JC, et al. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990 May;21(5):726-30. doi:10.1161/01.str.21.5.726; Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology. 2006 Oct 10;67(7):1272-4. doi:10.1212/01.wnl.0000238104.75563.2f; Delcourt C, Huang Y, Arima H, et al; INTERACT1 Investigators. Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. Neurology. 2012 Jul 24;79(4):314-9. doi:10.1212/WNL.0b013e318260cbba; Witt DM, Delate T, Hylek EM, et al. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. Thromb Res. 2013;132(6):770-5. doi:10.1016/j.thromres.2013.10.024; Hughes M, Lip GY; Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007 Oct;100(10):599-607. doi:10.1093/qjmed/hcm076; Smith EE, Rosand J, Knudsen KA, et al. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology. 2002 Jul 23;59(2):193-7. doi:10.1212/wnl.59.2.193; Nilsson OG, Lindgren A, Brandt L, Säveland H. Prediction of death in patients with primary intracerebral hemorrhage: a prospective study of a defined population. J Neurosurg. 2002 Sep;97(3):531-6. doi:10.3171/jns.2002.97.3.0531; Siddiqui FM, Bekker SV, Qureshi AI. Neuroimaging of hemorrhage and vascular defects. Neurotherapeutics. 2011 Jan;8(1):28-38. doi:10.1007/s13311-010-0009-x; Zubkov AY, Mandrekar JN, Claassen DO, et al. Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol. 2008 Oct;65(10):1320-5. doi:10.1001/archneur.65.10.1320; Сычев ДА, Остроумова ОД, Остроумова ТМ и др. Факторы риска лекарственно-индуцированных заболеваний. В кн.: Де ВА, Загородникова КА, Иващенко ДВ и др. Лекарственнo-индуцированные заболевания. Москва: Прометей; 2022. С. 31-450.; Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014 Oct 9;124(15):2450-8. doi:10.1182/blood-2014-07-590323; Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62. doi:10.1016/S0140-6736(13)62343-0; Steffel J, Collins R, Antz M, et al; External reviewers. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Oct 9;23(10):1612-76. doi:10.1093/europace/euab065; Tsai CT, Liao JN, Chiang CE, et al. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage. JAMA Netw Open. 2020 Jun 1;3(6):e206424. doi:10.1001/jamanetworkopen.2020.6424; Klijn CJ, Paciaroni M, Berge E, et al. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J. 2019 Sep;4(3):198-223. doi:10.1177/2396987319841187; Hindricks G, Potpara T, Dagres N, et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi:10.1093/eurheartj/ehaa612; Аракелян МГ, Бокерия ЛА, Васильева ЕЮ и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. doi:10.15829/1560-4071-2021-4594; Остроумова ОД, Остроумова ТМ. Антикоагулянтная терапия в рамках вторичной профилактики инсульта у пациентов с фибрилляцией предсердий. Неврология, нейропсихиатрия, психосоматика. 2022;14(3):94-100. doi:10.14412/2074-2711-2022-3-94-100; The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997 May 31;349(9065):1569-81.; Mantia C, Uhlmann EJ, Puligandla M, et al. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood. 2017 Jun 22;129(25):3379-85. doi:10.1182/blood-2017-02-767285; Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):287S-310S. doi:10.1378/chest.126.3_suppl.287S; Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015 Jul;46(7):2032-60. doi:10.1161/STR.0000000000000069; Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA. 1992 Sep 9;268(10):1292-300. doi:10.1001/jama.1992.03490100090033; Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke. 2005 Aug;36(8):1801-7. doi:10.1161/01.STR.0000174189.81153.85; Mazya M, Egido JA, Ford GA, et al; SITS Investigators. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012 Jun;43(6):1524-31. doi:10.1161/STROKEAHA.111.644815; Naidech AM, Bendok BR, Garg RK, et al. Reduced platelet activity is associated with more intraventricular hemorrhage. Neurosurgery. 2009 Oct;65(4):684-8; discussion 688. doi:10.1227/01.NEU.0000351769.39990; Campbell PG, Yadla S, Sen AN, et al. Emergency reversal of clopidogrel in the setting of spontaneous intracerebral hemorrhage. World Neurosurg. 2011 Jul-Aug;76(1-2):100-4; discussion 59-60. doi:10.1016/j.wneu.2011.02.010; Garcia-Rodriguez LA, Gaist D, Morton J, et al. Antithrombotic drugs and risk of hemorrhagic stroke in the general population. Neurology. 2013 Aug 6;81(6):566-74. doi:10.1212/WNL.0b013e31829e6ffa; Министерство здравоохранения Российской Федерации. Рубрикатор клинических рекомендаций. Ишемический инсульт и транзиторная ишемическая атака у взрослых. ID: 171. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/171_2 (дата обращения 09.07.2022).; Gulati S, Solheim O, Carlsen SM, et al. Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study. PLoS One. 2018 Aug 23;13(8):e0202575. doi:10.1371/journal.pone.0202575; Двойная антитромбоцитарная терапия при ишемической болезни сердца: обновленная версия 2017 года. Российский кардиологический журнал. 2018;(8):113-63. doi:10.15829/1560-4071-2018-8-113-163; Beshay JE, Morgan H, Madden C, et al. Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. J Neurosurg. 2010 Feb;112(2):307-18. doi:10.3171/2009.7.JNS0982; Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al; PATCH Investigators. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016 Jun 25;387(10038):2605-13. doi:10.1016/S0140-6736(16)30392-0; Halvorsen S, Storey RF, Rocca B, et al; ESC Working Group on Thrombosis. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2017 May 14;38(19):1455-62. doi:10.1093/eurheartj/ehw454; rlsnet.ru/drugs [интернет]. РЛС. Регистр лекарственных средств России. Доступно по ссылке: https://www.rlsnet.ru/ (дата обращения 13.07.2022).; Российское кардиологическое общество (РКО). Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4103. doi:10.15829/29/1560-4071-2020-4103; Российское кардиологическое общество (РКО). Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. doi:10.15829/29/1560-4071-2020-4076; Барбараш ОЛ, Дупляков ДВ, Затейщиков ДА и др. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(4):4449. doi:10.15829/1560-4071-2021-4449

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1925
https://doi.org/10.14412/2074-2711-2022-6-80-88

Ischemic stroke in senile patient with atrial fibrillation, decompensation of heart failure and type 2 diabetes mellitus - challenges in choosing approach to prevention of stroke

Συγγραφείς: A. Yu. Kuchina, S.V. Kakorin, N.A. Novikova

Πηγή: Emergency Cardiology. :48-56

Θεματικοί όροι: 2. Zero hunger, anticoagulants, ишемический инсульт, сахарный диабет, prevention of ischemic stroke, 3. Good health, atrial fi brillation, фибрилляция предсердий, вторичная профилактика, diabetes mellitus, ischemic stroke, антиагреганты, antiplatelets, антикоагулянты

Current approaches to the use of antiplatelet and anticoagulant drugs in pregnant women with thrombocytopenia caused by hemostasis activation ; Современные подходы к применению антиагрегантных и антикоагулянтных средств у беременных с тромбоцитопенией, обусловленной активацией системы гемостаза

Συγγραφείς: O. L. Mysik, M. S. Zainulina, О. Л. Мысик, М. С. Зайнулина

Πηγή: Obstetrics, Gynecology and Reproduction; Vol 15, No 2 (2021); 132-142 ; Акушерство, Гинекология и Репродукция; Vol 15, No 2 (2021); 132-142 ; 2500-3194 ; 2313-7347

Θεματικοί όροι: плацента-ассоциированные осложнения, thrombotic microangiopathies, preeclampsia, eclampsia, thrombophilia, anticoagulants, antiplatelet agents, placenta-associated complications, тромботические микроангиопатии, преэклампсия, эклампсия, тромбофилии, антикоагулянты, антиагреганты

Περιγραφή αρχείου: application/pdf

Relation: https://www.gynecology.su/jour/article/view/967/900; Blumenfeld Z., Brenner B. Thrombophilia-associated pregnancy wastage. Fertil Steril. 1999;72(5):765–74. https://doi.org/10.1016/s0015-0282(99)00360-x.; Borrelli A.L., Brillante M., Borzacchiello C., Berlingieri P. Hemocoagulative pathology and immunological recurrent abortion. Clin Exp Obstet Gynecol. 1997;24(1):39–40.; Caruso A., De Carolis S., Di Simone N. Antiphospholipid antibodies in obstetrics: new complexities and sites of action. Hum Reprod Update. 1999;5(3):267–76. https://doi.org/10.1093/humupd/5.3.267.; Старченко К.В. Значение определения резистентности к активированному протеину С и FV мутации Лейдена у беременных и родильниц с тромбозами: Автореф. дис. канд. мед. наук. М., 2000. 24 с.; Boden-Albala B., Sacco R.L., Lee H.S. et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke. 2008;39(l):30–5. https://doi.org/10.1161/STROKEAHA.107.496588.; Eldibany M.M., Caprini J A. Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med. 2007;131(6):872–84. https://doi.org/10.1043/1543-2165(2007)131[872:HATAO]2.0.CO;2.; Menke J., Lüthje L., Kastrup A., Larsen J. Thromboembolism in atrial fibrillation. Am J Cardiol. 2010;105(4):502–10. https://doi.org/10.1016/j.amjcard.2009.10.018.; Fujikura T., Benson R.C. Placentitis and fibrous occlusion of fetal vessels in the placentas of stillborn infants. Am J Obstet Gynecol. 1964;89:225–32 https://doi.org/10.1016/0002-9378(64)90715-x.; Kitzmiller J.L., Benirschke K. Immunofluorescent study of placental bed vessels in preeclampsia. Am J Obstet Gynecol. 1973;115(2):248–51. https://doi.org/10.1016/0002-9378(73)90293-7.; Naeye R.L. Placental infarction leading to fetal or neonatal death. A prospective study. Obstet Gynecol. 1977;50(5):583–8.; Fox H. The histopathology of placental insufficiency. J Clin Pathol Suppl (R Coll Pathol). 1976;10:1–8. https://doi.org/10.1136/jcp.s3-10.1.1.; Goddijn-Wessel T.A., Wouters M.G., van de Molen E.F. et al. Hyperhomocysteinaemia: a risk factor for placental abruption or infraction. Eur J Obstet Gynecol Reprod Biol. 1996;66(1):23–9. https://doi.org/10.1016/0301-2115(96)02383-4.; Palta A., Dhiman P. Thrombocytopenia in pregnancy. J Obstet Gynaecol. 2016;36(2):146–52. https://doi.org/10.3109/01443615.2015.1041893.; Gernsheimer T., James A.H., Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013;121(1):38–47. https://doi.org/10.1182/blood2012-08-448944.; Boehlen F., Hohlfeld P., Extermann P. et al. Platelet count at term pregnancy: a reappraisal of the threshold. Obstet Gynecol. 2000;95(1):29– 33. https://doi.org/10.1016/s0029-7844(99)00537-2.; Bergmann F., Rath W. The differential diagnosis of thrombocytopenia in pregnancy. Dtsch Arztebl Int. 2015;112(47):795–802. https://doi.org/10.3238/arztebl.2015.0795.; Jodkowska A., Martynowicz H., Kaczmarek-Wdowiak B., Mazur G. Thrombocytopenia in pregnancy – pathogenesis and diagnostic approach. Postepy Hig Med Dosw (Online). 2015;69:1215–21. https://doi.org/10.5604/17322693.1179649.; Мищенко А.Л. Противотромботическая терапия при различных клинических формах ДВС-синдрома в акушерстве. Акушерство и гинекология. 1999;(2):41–5.; Abalos E., Cuesta C., Grosso A.L. et al. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1–7. https://doi.org/10.1016/j.ejogrb.2013.05.005.; Ananth C.V., Keyes K.M., Wabner R.J. Pre-eclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ. 2013;347:f6564. https://doi.org/10.1136/bmj.f6564.; American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins – Obstetrics. Practice Bulletin No. 166: Thrombocytopenia in pregnancy. Obstet Gynecol. 2016;128(3):e43–53. https://doi.org/10.1097/AOG.0000000000001641.; Айламазян Э.К., Мозговая Е.В. Гестоз: теория и практика. М.: МЕДпресс-информ, 2008. 272 с.; Дисфункция эндотелия: причины, механизмы, фармакологическая коррекция. Под ред. H.H. Петрищева. СПб.: Изд-во СПбГМУ, 2003. 181 с.; Мусаев З.М., Пицхелаури Е.Г. Гестозы: актуальные вопросы ранней диагностики и акушерской тактики. Вопросы гинекологии, акушерства и перинатологии. 2002;1(1):60–3.; Erez O., Mastrolia S.A., Thachil J. Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. Am J Obstet Gynecol. 2015;213(4):452–63. https://doi.org/10.1016/j.ajog.2015.03.054.; Galloway S., Lyons G. HELLP, coagulopathy and renal failure – further lessons. Int J Obstet Anesth. 2003;12(1):35–9. https://doi.org/10.1016/s0959-289x(02)00134-6.; Кулаков В.И., Мурашко Л.Е., Бурлев В.А. Клинико-биохимические аспекты патогенеза гестоза. Акушерство и гинекология. 1995;(6):3–5.; Мищенко А.Л., Макацария А.Д. Вопросы циркуляторной адаптации системы гемостаза при физиологической беременности и синдром диссеминированного внутрисосудистого свертывания. Акушерство и гинекология. 1997;(1):38–41.; Burrows R.F., Hunter D.J., Andrew M., Kelton J.G. A prospective study investigating the mechanism of thrombocytopenia in preeclampsia. Obstet Gynecol. 1987;70(3 Pt 1):334–8.; Kaibara M., Marumoto Y., Taniguchi I., Kobayashi T. Hemorheological studies on platelet counts and size in normal pregnancy and pregnancies with preeclampsia and intrauterine growth retardation. Nippon Sanka Fujinka Gakkai Zasshi. 1989;41(9):1380–1.; Сидорова И.С. Гестоз. Учебное пособие. М.: Медицина, 2003. 415 с.; Erez O., Hallak M., Luber A. et al. Platelets activation marker as predictor of severe preeclampsia in patients with history of preeclampsia. Am J Obstet Gynecol. 2001;185(6):S175. https://doi.org/10.1016/s00029378(01)80374-4.; Салахеева Г.С., Понукалина Е.В., Глухова Т.Н., Чеснокова Н.П. Динамика изменений показателей периферической крови у беременных с гестозом различной степени тяжести. Фундаментальные исследования. 2006;(10):20–3.; Репина М.А., Сумская Г.Ф., Лапина Е.Н., Кузьмина-Крутецкая С.Р. Особенности течения беременности у женщин с наследственными формами тромбофилии. Журнал акушерства и женских болезней. 2026;55(2):3–9.; Савельева Г.М., Федорова М.В., Клименко П.А., Сичинава Л.Г. Плацентарная недостаточность. М.: Медицина, 1991. 276 с.; Belfort M.A., Uys P., Dommise J., Davey D.A. Hemodynamic changes in gestational proteinuric hypertension. The effects of rapid volume expansion and vasodilator therapy. BJOG. 1989;96:641–9. https://doi.org/10.1111/j.1471-0528.1989.tb03276.x.; Гениевская М.Г., Макацария А.Д. Длительная терапия с применением фраксипарина у беременных с антифосфолипидным синдромом. Акушерство и гинекология. 2002;(1):24–7.; Dunn J.C., Sorcin E.M. Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs. 1996;52(2):276–305. https://doi.org/10.2165/00003495-199652020-00011.; Hirsh J., Warkentin T.E., Shaughnessy S.G. et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest. 2001;119(1 Suppl):64S– 94S. https://doi.org/10.1378/chest.119.1_suppl.64s.; Корнюшина Е.А. Клинико-патогенетическое обоснование применения курантила и фраксипарина у беременных с невынашиванием и тромбофилией: Автореф. дис. канд. мед. наук. СПб., 2011. 24 с.; https://www.gynecology.su/jour/article/view/967

Διαθεσιμότητα: https://www.gynecology.su/jour/article/view/967
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.178

2020 Russian and European clinical practice guidelines for the management of NSTEMI patients: have approaches to antithrombotic therapy been simplified? ; Российские и европейские рекомендации 2020 года по ведению пациентов с острым коронарным синдромом без подъема сегмента ST: упростились ли подходы к антитромботической терапии?

Συγγραφείς: O. L. Barbarash, V. V. Kashtalap, О. Л. Барбараш, В. В. Кашталап

Συνεισφορές: Публикация подготовлена в рамках сотрудничества с Научно-образовательным центром мирового уровня «Кузбасс».

Πηγή: Complex Issues of Cardiovascular Diseases; Том 10, № 2 (2021); 92-101 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 10, № 2 (2021); 92-101 ; 2587-9537 ; 2306-1278

Θεματικοί όροι: Геморрагический риск, Antiplatelets, Anticoagulants, Ischemic and hemorrhagic risk, Антиагреганты, Антикоагулянты, Ишемический риск

Περιγραφή αρχείου: application/pdf

Relation: https://www.nii-kpssz.com/jour/article/view/856/562; Kaштaлaп В.В., Барбараш O.H. Aкгуaльные проблемы антитромботической терапии при остром коронарном синдроме (по материалам Европейского конгресса кардиологов 2017). Медицинский совет. 2017; 12: 82-88. doi:10.21518/2079-701X-2017-12-82-88.; Здравоохранение в России. 2017: статистический сборник. М.: Росстат; 2019. 170 с.; Оганов Р.Г., Концевая А.В., Калинина А.М. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2011;10(4):4-9. doi:10.15829/1728-8800-2011-4-4-9; Kлинические рекомендации Oстрый коронарный синдром без подъема сегмента ST электрокардиограммы. Режим доступа: http://cr.rosminzdrav.ru/schema/154_3 (дата обращения 12.02.2021); Collet J.P., Thiele Н., Barbato Е., Barthelemy О., Bauersachs J., Bhatt D.L., Dendale P., Dorobantu M., Edvardsen T., Folliguet T., Gale C.P., Gilard M., Jobs A., Juni P., Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten F.H., Sibbing D., Siontis G.C.M.; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367. doi:10.1093/eurheartj/ehaa575.; Rex S., Beaulieu L.M., Perlman D.H., Vitseva О., Blair P.S., McComb M.E., Costello C.E., Freedman J.E. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release. Thromb Haemost. 2009;102(1):97-110. doi:10.1160/TH08-08-0513.; Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., Horrow J., Husted S., James S., Katus H., Mahaffey K.W., Scirica B.M., Skene A., Steg P.G., Storey R.F., Harrington R.A.; PLATO Investigators, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. doi:10.1056/NEJMoa0904327.; Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Neumann F.J., Ardissino D., De Servi S., Murphy S.A., Riesmeyer J., Weerakkody G., Gibson C.M., Antman E.M.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. doi:10.1056/NEJMoa0706482.; Schupke S., Neumann F.J., Menichelli M., Mayer K., Bernlochner I., Wohrle J., Richardt G., Liebetrau C., Witzenbichler B., Antoniucci D., Akin I., Bott-Flugel L., Fischer M., Landmesser U., Katus H.A., Sibbing D., Seyfarth M., Janisch M., Boncompagni D., Hilz R., Rottbauer W., Okrojek R., Mollmann H., Hochholzer W., Migliorini A., Cassese S., Mollo P., Xhepa E., Kufner S., Strehle A., Leggewie S., Allali A., Ndrepepa G., Schuhlen H., Angiolillo D.J., Hamm C.W., Hapfelmeier A., Tolg R., Trenk D., Schunkert H., Laugwitz K.L., Kastrati A.; ISAR-REACT 5 Trial Investigators. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019;381(16):1524-1534. doi:10.1056/NEJMoa1908973.; Costa F., van Klaveren D., James S., Heg D., Raber L., Feres F., Pilgrim T., Hong M.K., Kim H.S., Colombo A., Steg P.G., Zanchin T., Palmerini T., Wallentin L., Bhatt D.L., Stone G.W., Windecker S., Steyerberg E.W., Valgimigli M.; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025-1034. doi:10.1016/S0140-6736(17)30397-5.; Mehran R., Baber U., Sharma S.K., Cohen D.J., Angiolillo D.J., Briguori C., Cha J.¥., Collier T., Dangas G., Dudek D., Dzavik V., Escaned J., Gil R., Gurbel P., Hamm C.W., Henry T., Huber K., Kastrati A., Kaul U., Kornowski R., Krucoff M., Kunadian V., Marx S.O., Mehta S.R., Moliterno D., Ohman E.M., Oldroyd K., Sardella G., Sartori S., Shlofmitz R., Steg P.G., Weisz G., Witzenbichler B., Han ¥.L., Pocock S., Gibson C.M. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019;381(21):2032-2042. doi:10.1056/NEJMoa1908419; Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, ¥usuf S., Mehta S.R., Chrolavicius S., Afzal R., Pogue J., Granger C.B., Budaj A., Peters R.J., Bassand J.P., Wallentin L., Joyner C., Fox K.A. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464-76. doi:10.1056/NEJMoa055443.

Διαθεσιμότητα: https://www.nii-kpssz.com/jour/article/view/856
https://doi.org/10.17802/2306-1278-2021-10-2-92-101

Антиагреганты при заболеваниях периферических артерий: доказательная база, международные рекомендации

Πηγή: Качественная клиническая практика, Vol 0, Iss 2, Pp 69-79 (2018)

Θεματικοί όροι: антиагреганты, заболевания периферических артерий, аспирин, клопидогрел, петоксифиллин, цилостазол, тиклопидин, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

Περιγραφή αρχείου: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/383; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

Σύνδεσμος πρόσβασης: https://doaj.org/article/62676bd3588840c3ad330ea1555b5820

Cost-minimization analysis of application acetylsalicylic acid in cardiac elderly patients

Συγγραφείς: D. Yu. Belousov, E. V. Afanasyeva

Πηγή: Качественная клиническая практика, Vol 0, Iss 1, Pp 3-8 (2018)

Θεματικοί όροι: фармакоэкономика, анализ минимизации затрат, ишемическая болезнь сердца, антиагреганты, ацетилсалициловая кислота, нпвп-ассоциированная гастропатия, pharmacoeconomics, cost-minimization analysis, coronary heart disease, antiplatelet agents, acetylsalicylic acid, nsaid-associated gastropathy, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

Περιγραφή αρχείου: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/3; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

Σύνδεσμος πρόσβασης: https://doaj.org/article/a657be05b0b340d0a81b31c5063dafbd

Фармакологические основы применения противоишемических и антиатеросклеротических препаратов у пациентов с доброкачественной гиперплазией предстательной железы ; Pharmacological basis for the use of anti-ischemic and anti-atherosclerotic drugs in patients with benign prostatic hyperplasia

Συγγραφείς: Mazurin, I. S., Zolotukhin, O. V., Madikin, Y. Y., Мазурин, И. С., Золотухин, О. В., Мадыкин, Ю. Ю.

Θεματικοί όροι: BENIGN PROSTATIC HYPERPLASIA (BPH), CHRONIC PELVIC ISCHAEMIA, VASCULAR ATHEROSCLEROSIS, ISCHEMIC CHANGES, SNMP – SYMPTOMS OF THE LOWER URINARY TRACT, STATINS, ANTIPLATELET AGENTS, ДОБРОКАЧЕСТВЕННАЯ ГИПЕРПЛАЗИЯ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ (ДГПЖ), ХРОНИЧЕСКАЯ ИШЕМИЯ ОРГАНОВ МАЛОГО ТАЗА, АТЕРОСКЛЕРОЗ СОСУДОВ, ИШЕМИЧЕСКИЕ ИЗМЕНЕНИЯ, СНМП – СИМПТОМЫ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ, СТАТИНЫ, АНТИАГРЕГАНТЫ

Περιγραφή αρχείου: application/pdf

Relation: Уральский медицинский журнал. 2020. № 5(188).; http://elib.usma.ru/handle/usma/19013

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/19013